Table 1.
Results of basic evaluation of POI: hormonal parameters, DEXA results, and autoimmune screening
| Median (IQR) | Number (frequency) of abnormal results | |
|---|---|---|
| Hormonal parameters | ||
| Total estradiol (pg/mL) | 14 (7; 62) | – |
| FSH (mIU/mL) | 77.4 (39.6; 115.2) | – |
| LH (mIU/mL) | 45.1 (26.2; 62.3) | – |
| AMH (ng/mL) | 0.01 (0.01; 0.08) | – |
| 25OH Vit D (nmol/L) | 59.1 (40.8; 78.6) | – |
| DEXA results | ||
| Lumbar spine T-score | −1.2 (−2.1; −0.5) | – |
| Femoral T-score | −0.8 (−1.6; −0.2) | – |
| Minimal T-score | −1.4 (−2.1; −0.2) | – |
| DEXA interpretation | ||
| Osteopenia | – | 28 (48.3) |
| Osteoporosis | – | 7 (12.1) |
| Autoimmune screening | ||
| TGAb (U/mL) | 11.0 (0;18.5) | 12 (20.7)* |
| TPOAb (U/mL) | 14.0 (7.5;38.0) | 14 (24.1)* |
| TRAb (U/mL) | 0 (0;0.7) | 0* |
| ANA/ANF (HEp-2 titer) | 0 (0;0) | 1 (1.7)*,# |
| ENA subsets | – | 3 (5.2)* |
| Anti-dsDNA (IU/mL) | 0 (0;0) | 0* |
| Anti-Scl-70 (U/mL) | 0.8 (0;1.0) | 0* |
| Anti-Sm (U/mL) | 1.0 (0.6;1.4) | 1 (1.7)* |
| Anti-U1RNP (U/ml) | 0.6 (0.3;1.0) | 0* |
| Anti-Jo-1 (U/mL) | 0 (0;0.7) | 0* |
| Anti-CENP-B (U/mL) | 0 (0;0.5) | 0* |
| Anti-Ro/SSA (U/mL) | 0 (0;0) | 1 (1.7)* |
| Anti-SSB/La (U/mL) | 0 (0;0) | 0* |
| aCL IgM (U/mL) | 0 (0;1.6) | 2 (3.4)* |
| aCL IgG (U/mL) | 1.1 (0;1.4) | 2 (3.4)* |
| Anti-B2GPI IgM (U/mL) | 0.6 (0;1.3) | 2 (3.4)* |
| Anti-B2GPI IgG (U/mL) | 0.8 (0;1.9) | 2 (3.4)* |
| HbA1c (mmol) | 30 (29;32) | 0* |
| Any autoimmune marker positive | 21 (36.2) | |
*Multiple selections possible
#The patient who was positive for ANA/ANF (HEp-2 titer) revealed a “speckled” ANA/ANF Hep-2 pattern